natgillin/translations-raw huggingface dataset:
Studies in human liver microsomes and recombinant enzyme systems have shown that maraviroc does not inhibit any of the major P450 enzymes at clinically relevant concentrations (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4).
Študije na človeških jetrnih mikrosomih in rekombinantnih encimskih sistemih so pokazale, da maravirok v klinično pomembnih koncentracijah ne zavira nobenega od pomembnih encimov P450 (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali CYP3A4).
Studies in human liver microsomes showed that artenimol was metabolised by the UDP-glucuronosyltransferase (UGT1A9 and UGT2B7) to α- artenimol-G with no cytochrome P450-mediated metabolism.
Študije na mikrosomih človeških jeter so pokazale, da je artenimol presnavljala UDP-glukuronosiltransferaza (UGT1A9 in UGT2B7) v α-artenimol-G brez presnove, v kateri sodeluje citokrom P450.
Studies in juvenile animals have shown adverse effects of trametinib which had not been observed in adult animals (see section 5.3).
V študijah na mladih živalih so se pokazali neželeni učinki trametiniba, ki jih pri odraslih živalih niso opažali (glejte poglavje 5.3).
Studies in lactating rats indicate that maraviroc is extensively secreted into rat milk.
Študije pri doječih podganah kažejo, da se maravirok pri teh živalih v veliki meri izloča v mleko.
Studies in new-born infants or infants and toddlers under 2 years of age have not been conducted.
Študij pri novorojenčkih, dojenčkih in malih otrocih do 2 let starosti niso opravili.
Studies in Non-CCR5-tropic Treatment-Experienced Patients:
Študije pri ne-CCR5-tropnih, predhodno že zdravljenih bolnikih:
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels (see sections 4.8 and 5.1).
Študije pri bolnikih, starih 13 17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina (glejte poglavji 4.8 in 5.1).
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels (see sections 4.8 and 5.1).
Študije pri bolnikih, starih 13-17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina(glejte poglavji 4.8 in 5.1).
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels (see sections 4.8 and 5.1).
Študije pri bolnikih, starih 13-17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina.
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels (see sections 4.8 and 5.1).
Študije pri bolnikih, starih 13-17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina. (glejte poglavji 4.8 in 5.1).
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels(see sections 4.8 and 5.1).
Študije pri bolnikih, starih 13-17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina (glejte poglavji 4.8 in 5.1).
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels. (see sections 4.8 and 5.1).
Študije pri bolnikih, starih 13-17 let kažejo na različne neželene učinke, vključno s povečanjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina (glejte poglavji 4.8 in 5.1).
Studies in patients with decompensated cirrhosis (CPT Class B)
Študije pri bolnikih z dekompenzirano cirozo (CPT stopnje B)
Studies in patients with hepatic insufficiency have not been performed.
Študije pri bolnikih z jetrno insuficienco še niso bile opravljene.
Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction.
Študije pri bolnikih z oslabljenim delovanjem ledvic kažejo, da okvara ledvic prizadene izločanje lamivudina.
Studies in patients without cirrhosis and patients with compensated cirrhosis
Študije pri bolnikih brez ciroze in bolnikih s kompenzirano cirozo
Studies in pregnant rats with alogliptin plus metformin as combination treatment have shown reproductive toxicity at approximately 5-20 times (for metformin and alogliptin respectively) the human exposure at the recommended dose.
Študije pri brejih podganah, ki so prejemale kombinacijo alogliptina in metformina, so pokazale vpliv na sposobnost razmnoževanja pri izpostavljenosti, ki je bila približno 5-20-krat večja od izpostavljenosti človeka pri priporočenem odmerku.
Studies in rabbits have shown peak concentrations of 20 ng/g of the free acid in aqueous humour one to two hours after topical dosing of Travoprost 40 µg/mL eye drops, solution.
Študije na kuncih so pokazale najvišjo koncentracijo proste kisline v prekatni vodki 20 ng/g eno do dve uri po topikalni uporabi kapljic za oko s travoprostom v odmerku 40 µg/ml.
Studies in rabbits have shown reproductive toxicity (see section 5.3).
Študije na kuncih so pokazale škodljiv vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
Studies in rats and rabbits showed reproductive toxicity at high exposures.
Študije na podganah in kuncih so pri večji izpostavljenosti pokazale reproduktivno toksičnost.
Studies in rats have demonstrated that atazanavir is excreted in the milk.
Študije na podganah so pokazale, da se atazanavir izloča v mleko.
Studies in rats have shown excretion of tolvaptan in breast milk.
Študije na podganah so pokazale, da se tolvaptan izloča v mleko.
Studies in rats have shown no effect on fertility in males and females (see section 5.3).
Študije na podganah niso pokazale učinka na plodnost pri samcih in samicah (glejte poglavje 5.3).
Studies in rats have shown that radioactive labelled active substance-related materials distribute widely in the body following single and multiple oral doses of 14C-nepafenac.
Študije pri podganah so pokazale, da se radioaktivno označene snovi, sorodne učinkovini zdravila, po enkratnem ali večkratnem peroralnem odmerjanju 14C-nepafenaka, široko porazdelijo po telesu.
Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia.
Študije pri podganah so pokazale, da je bila distocija med porodom zaradi hipokalciemije povezana z zdravljenjem z alendronatom.
Studies in treatment naïve patients
Študije zdravljenja predhodno nezdravljenih bolnikov
Studies in Treatment-Naïve Patients
Študije pri predhodno še nezdravljenih bolnikih
Studies in types of surgery other than CABG procedures included patients with ASA (American Society of Anaesthesiology) Physical Status Class I-III only.
Študije drugih tipov operacijskih posegov, razen postopkov CABG, so vključevale le bolnike s kliničnim statusom ASA (ASA - American Society of Anaesthesiology), razreda I-III.
Studies in unvaccinated children (12 -23 months) with Prevenar (7-valent) demonstrated that 2 doses were required to achieve serum IgG concentrations for 6B and 23F similar to those induced by a 3- dose infant series.
Študije pri necepljenih otrocih (v starosti od 12 do 23 mesecev) s cepivom Prevenar (7-valentnim) so pokazale, da sta bila za to, da bi dosegli koncentracije IgG v serumu za 6B in 23F, podobne tistim, ki so bile izzvane s tremi odmerki za dojenčke, potrebna dva odmerka.
Studies in unvaccinated children (12-23 months) with Prevenar (7-valent) demonstrated that 2 doses were required to achieve serum IgG concentrations for 6B and 23F similar to those induced by a 3- dose infant series.
Študije pri necepljenih otrocih (v starosti od 12 do 23 mesecev) s cepivom Prevenar (7-valentnim) so pokazale, da sta bila za to, da bi dosegli koncentracije IgG v serumu za 6B in 23F, podobne tistim, ki so bile izzvane s tremi odmerki za dojenčke, potrebna dva odmerka.
Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5.
Študije in vitro so pokazale, da je tadalafil selektivni inhibitor PDE5.
Studies in vitro indicate that boceprevir primarily undergoes metabolism through the aldo- ketoreductase (AKR)-mediated pathway to ketone-reduced metabolites that are inactive against HCV.
Študije in vitro kažejo, da se boceprevir primarno presnovi po aldo-ketoreduktazni (AKR) poti v ketonske reducirane presnovke, ki so proti HCV neaktivni.
Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg.
Študije na zdravih prostovoljcih so pokazale, da ima memantin linearno farmakokinetiko pri odmerkih, velikih od 10 do 40 mg.
Studies including patients with renal insufficiency (creatinine clearance < 30 ml/min for the monotherapy, and < 60 ml/min for the combination regimen) have not been conducted and therefore Yondelis must not be used in this patient population (see section 4.4).
Študije, ki so vključevale bolnike z motnjami delovanja ledvic (očistek kreatinina < 30 ml/min pri monoterapiji in < 60 ml/min pri kombiniranem režimu) niso bile izvedene, zato zdravila Yondelis ni dovoljeno uporabiti za to populacijo bolnikov (glejte poglavje 4.4).
Studies looked at how Melosus was absorbed and its effects in the body, in comparison with Metacam.
V študijah so proučevali absorbiranje zdravila Melosus in njegove učinke na telo v primerjavi z zdravilom Metacam.
Studies NV-02B-007 (GLOBE) and CLDT600A2303 - cumulative genotypic resistance rates
Študiji NV-02B-007 (GLOBE) in CLDT600A2303 - kumulativni deleži genotipske rezistence
Studies of Cubicin with anticoagulants other than warfarin have not been conducted.
Študij z zdravilom Cubicin in drugimi antikoagulansi razen varfarina niso izvajali.
Studies of immediate-release exenatide in combination with basal insulin
Študije eksenatida v obliki s takojšnjim sproščanjem v kombinaciji z bazalnim insulinom
Studies of MabThera in patients with early arthritis (patients without prior methotrexate treatment and patients with an inadequate response to methotrexate, but not yet treated with TNF-alpha inhibitors) have met their primary endpoints.
V preskušanjih z zdravilom MabThera pri bolnikih z zgodnjim artritisom (bolniki, ki se še niso zdravili z metotreksatom in bolniki z nezadostnim odzivom na metotreksat, ki se še niso zdravili z zaviralci TNF-alfa) so bili primarni cilji doseženi.
Studies of mirabegron using human liver microsomes and recombinant human CYP enzymes showed that mirabegron is a moderate and time- dependent inhibitor of CYP2D6 and a weak inhibitor of CYP3A.
Študije mirabegrona s človeškimi jetrnimi mikrosomi in rekombinantnimi človeškimi encimi CYP so pokazale, da mirabegron zmerno in od časa odvisno zavira CYP2D6 in da šibko zavira CYP3A.
Studies of sitagliptin in combination with metformin
Študije sitagliptina v kombinaciji z metforminom
Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects of tenofovir alafenamide on fertility parameters, pregnancy, or fetal development (see section 5.3).
Študije alafenamidtenofovirata na živalih niso pokazale škodljivih učinkov alafenamidtenofovirata na parametre plodnosti, nosečnost ali razvoj plodu (glejte poglavje 5.3).
Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3).
Študije alafenamidtenofovirata na živalih niso pokazale škodljivih učinkov na parametre plodnosti, nosečnost ali razvoj plodu (glejte poglavje 5.3).
Studies of the effect of Myocet on other substances are also lacking.
Študij o učinku zdravila Myocet na druge snovi tudi ni.
Studies on Patients co-infected with hepatitis B and/or hepatitis C virus
Študije pri bolnikih, hkrati okuženih z virusom hepatitisa B in/ali hepatitisa C
Studies on reproductive and developmental toxicity have not been performed.
Študij reproduktivne in razvojne toksičnosti niso izvedji.
Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305: Intent-to-Treat Analysis Set
Študije R076477-SCH-303, R076477-SCH-304 in R076477-SCH-305: Analiza populacije, vključene v študije (ITT-Intent-to-Treat)
Studies several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Študije z več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena, niso pokazale nezdružljivosti z zdravilom Zoledronska kislina Teva.
Studies show that Cancidas treatment can lead to favourable responses in patients with fungal infections, including improvement of symptoms and the clearing of fungus from patient’s body.
Študije so pokazale, da se bolniki z glivno okužbo lahko pozitivno odzovejo na zdravljenje z zdravilom Cancidas, tudi z izboljšanjem simptomov in odstranitvijo glive iz bolnikovega telesa.
Studies show that Elocta is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is in line with what is expected for medicines of its kind.
Študije kažejo, da je zdravilo Elocta učinkovito pri preprečevanju in zdravljenju epizod krvavitve pri bolnikih s hemofilijo A, njegova varnost pa je v skladu s pričakovano varnostjo tovrstnih zdravil.
Studies show that nitric oxide exhibits pulmonary pharmacodynamic effects at intra-airway concentrations as low as 1 ppm.
Študije so pokazale, da ima dušikov oksid farmakodinamične učinke na pljuča že pri tako nizkih koncentracijah v dihalih, kot je 1 ppm.
Studies show that Numient is effective at reducing symptoms in patients with early and late stage Parkinson’s disease.
Študiji kažeta, da je zdravilo Numient učinkovito pri zmanjševanju simptomov pri bolnikih s Parkinsonovo boleznijo v zgodnji in pozni fazi.
Studies showed Oncaspar to be effective in patients with ALL, including patients who were allergic to other medicines containing asparaginase.
Študije so pokazale, da je zdravilo Oncaspar učinkovito pri bolnikih z ALL, vključno z bolniki, ki so alergični na druga zdravila, ki vsebujejo asparaginazo.
Studies showed that sevoflurane could be used safely for maintenance of anaesthesia with several other medicines commonly used in dogs before or during operations.
Študije so pokazale, da je sevofluran mogoče varno uporabljati za vzdrževanje anestezije skupaj z več drugimi zdravili, ki se pogosto uporabljajo pri psih pred operacijami ali med njimi.
Studies supporting the efficacy of Gardasil 9 against HPV Types 31, 33, 45, 52, and 58
Študije, ki potrjujejo učinkovitost cepiva Gardasil 9 proti tipom HPV 31, 33, 45, 52 in 58
Studies supporting the efficacy of Gardasil 9 against HPV Types 6, 11, 16, 18
Študije, ki podpirajo učinkovitost cepiva Gardasil 9 proti tipom HPV 6, 11, 16 in 18
Studies to Assess Cardiac Effects
Študije za oceno učinkov na srce
Studies to determine the effect of orbifloxacin on fertility in dogs have not been conducted.
Študije, ki bi pokazale kakšen je vpliv orbifloksacina na plodnost, niso bile narejene.
Studies to determine the effects of Reconcile tablets on breeding, pregnant or lactating dogs have not been conducted and thus the use in pregnant and lactating dogs is not recommended.
Študij o učinkih tablet Reconcile na vzrejne, breje ali doječe psice ni in se zato uporaba pri brejih ali doječih psicah ne priporoča.
Studies to investigate genotoxicity, carcinogenicity, toxicity to reproduction or embryo-foetal development have not been conducted.
Študij za preučitev genotoksičnost, kancerogenosti, vpliva na sposobnost razmnoževanja in embrio- fetalnega razvoja niso izvedli.
Studies using liquid palivizumab
Študije, v katerih so uporabljali palivizumab v tekoči obliki
Studies using lyophilised palivizumab
Študije, v katerih so uporabljali palivizumab v liofilizirani obliki
Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.
Raziskave, pri katerih so uporabljali sevofluranske anestezijske protokole, ki so vključevali atropin ali glikopirolat kot sredstva za premedikacijo, so pokazale, da so ti antiholinergiki pri psih kompatibilni s sevofluranom.
Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.
Raziskave, pri katerih so uporabljali sevofluranske anestezijske protokole, ki so vključevali atropin ali glikopirolat kot sredstvi za premedikacijo, so pokazale, da so ti antiholinergiki pri psih kompatibilni s sevofluranom.
Studies were also carried out to show that Grastofil produces levels of the active substance in the body that are comparable to the reference medicine, Neupogen.
Opravili so tudi študije, v katerih so pokazali, da zdravilo Grastofil doseže podobne ravni zdravilne učinkovine v telesu kot referenčno zdravilo Neupogen.
Studies were carried out in dogs, comparing the effectiveness of SevoFlo to that of other anaesthetic agents, such as isoflurane (another anaesthetic gas), thiopental, propofol, and ketamine plus diazepam, and SevoFlo’s effectiveness at both causing and maintaining anaesthesia was investigated.
Izvedene so bile študije pri psih, v katerih so primerjali učinkovitost zdravila SevoFlo z učinkovitostjo drugih anestetikov, kot so na primer izofluran (drug anestezijski plin), tiopental, propofol in ketamin z diazepamom, ter učinkovitost zdravila SevoFlo pri povzročanju in vzdrževanju anestezije.
Studies were carried out to show that Budesonide/Formoterol Teva Pharma B.V. is bioequivalent to the reference medicine (i.e. produces the same level of the active substance in the body) and that the two medicines act in the same way.
Izvedene so bile študije, ki so pokazale, da je zdravilo Budesonide/Formoterol Teva Pharma B.V. biološko enakovredno referenčnemu zdravilu (tj. da dosega enako raven zdravilne učinkovine v telesu) in da obe zdravili enako delujeta.
Studies with abacavir demonstrate a CSF to plasma AUC ratio of between 30 to 44%.
Študije z abakavirjem kažejo, da je razmerje med CST in plazemsko AUC med 30 do 44 %.
Studies with an 11-valent vaccine formulation representative for Synflorix revealed no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity.
Na osnovi običajnih študij farmakološke varnosti pri enkratnem in ponavljajočih se odmerkih, študije z 11-valentno formulacijo, ki je reprezentativna cepivu Synflorix, ne kažejo posebnega tveganja za človeka.
Studies with glass bottles, as well as several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9 %) solution for injection or 5 % w/v glucose solution), showed no incompatibility with zoledronic acid.
Študije s steklenicami in s številnimi vrstami infuzijskih vrečk in infuzijskih linij iz polivinilklorida, polietilena in polipropilena (napolnjene z 9 mg/ml (0,9-odstotno) raztopino natrijevega klorida za injekcije ali 5-odstotne m/v raztopine glukoze) ni pokazala nezdružljivosti z zoledronsko kislino.
Studies with glass bottles, as well as several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution), showed no incompatibility with zoledronic acid.
Študije s steklenicami in s številnimi vrstami infuzijskih vrečk in infuzijskih linij iz polivinilklorida, polietilena in polipropilena (napolnjene z 9 mg/ml (0,9-odstotno) raztopino natrijevega klorida za injekcije ali 5-odstotne m/v raztopine glukoze) ni pokazala nezdružljivosti z zoledronsko kislino.
Studies with glass bottles, several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution) showed no incompatibility with zoledronic acid.
Študije s steklenicami, več vrstami infuzijskih vrečk in infuzijskih linij, izdelanih iz polivinilklorida, polietilena in polipropilena (napolnjenih z 9 mg/ml (0,9-odstotna) m/v raztopina natrijevega klorida za injekcije, niso pokazale nezdružljivosti z zoledronsko kislino.
Studies with glass bottles, several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution) showed no incompatibility with zoledronic acid.
Študije s steklenicami, več vrstami infuzijskih vrečk in infuzijskih linij, izdelanih iz polivinilklorida, polietilena in polipropilena (napolnjenih z 9 mg/ml (0,9-odstotno) raztopino natrijevega klorida za injekcije ali 5-odstotno m/v raztopino glukoze), niso pokazale nezdružljivosti z zoledronsko kislino.
Studies with Higher Dose Combinations of dextromethorphan / quinidine
Študije z večjim odmerkom kombinacije dekstrometorfana/kinidina
Studies with Kuvan involved adults and children of all ages.
V študije zdravila Kuvan so vključili odrasle in otroke vseh starosti.
Studies with other interferons have demonstrated species specificity.
Tudi raziskave na drugih interferonih so pokazale vrstno
Studies with other interferons have demonstrated species specificity.
Študije z drugimi interferoni so pokazale vrstno specifičnost, vendar pa so nekatere vrste opic, npr.
Studies with polyolefin bags (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution), showed no incompatibility with Zoledronic acid Mylan.
Študije s poliolefinskimi vrečkami (vnaprej napolnjenimi z 9 mg/ml (0.9 %) raztopino natrijevega klorida za injiciranje ali 5-odstotno m/V raztopino glukoze niso pokazale inkompatibilnosti z zdravilom Zoledronska kislina Mylan.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with Zoledronic Acid Accord.
Študije z več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena, niso pokazale nezdružljivosti z zdravilom Zoledronska kislina Accord.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with Zoledronic acid Teva.
Študije z več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena, niso pokazale nezdružljivosti z zdravilom Zoledronska kislina Teva.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Študije z več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena, niso pokazale nezdružljivosti z zoledronsko kislino.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with Zometa.
Študije z več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena, niso pokazale nezdružljivosti z zdravilom Zometa.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with Zometa.
Študije z več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena, niso pokazale nezdružljivosti z zdravilom Zometa..
Studies with single oral doses in normal subjects and with multiple oral doses in patients with type 2 diabetes mellitus have shown significant absorption of glimepiride within 1 h after administration and Cmax at approximately 2.5 h.
Študije s posamičnimi peroralnimi odmerki pri zdravih preiskovancih in z večkratnimi peroralnimi odmerki pri bolnikih z diabetesom mellitusom tipa 2 so pokazale pomembno absorpcijo glimepirida v 1 uri po uporabi in Cmax po približno 2,5 ure.